title: Muscle strength and body composition during the transition phase in patients treated with recombinant GH to final height.
abstract: We assessed body composition and muscle strength during the transition phase in 18 growth hormone (GH) deficient males treated with recombinant GH to final height and 18 controls. According to peak-stimulated GH and basal insulin-like growth factor-1 (IGF-1) during the transition phase, patients were subdivided into GH deficient (GHD-TP, n=9) and GH sufficient (GHS-TP, n=9) groups. Assessments included lean and fat body mass and bone mineral density (BMD), all measured by dual-energy X-ray absorptiometry, and dynamic knee muscle strength, assessed by isokinetic dynamometer. Total body and lumbar spine BMD and muscle strength were lower in GHD-TP patients when compared with GHS-TP and controls (all p<0.05), whereas lean and fat body mass were lower in both GHD-TP and GHS-TP patients when compared with controls (p<0.05). These findings suggest that administration of recombinant GH to final height is not sufficient to provide normal body composition and muscle strength in young male patients with GH deficiency.
authors.forename: Marilza de Jesus
authors.initials: Mde J
authors.lastname: Modesto
authors.forename: Nadia Mohamad
authors.initials: NM
authors.lastname: Amer
authors.forename: Oscar
authors.initials: O
authors.lastname: Erichsen
authors.forename: Sara
authors.initials: S
authors.lastname: Hernandez
authors.forename: Cláudia Duarte
authors.initials: CD
authors.lastname: dos Santos
authors.forename: Julienne Ângela Ramires
authors.initials: JÂ
authors.lastname: de Carvalho
authors.forename: Rosana Marques
authors.initials: RM
authors.lastname: Pereira
authors.forename: Suzana Nesi
authors.initials: SN
authors.lastname: França
authors.forename: Luiz
authors.initials: L
authors.lastname: De Lacerda
mesh_terms: D000293:Adolescent; D000328:Adult; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D001827:Body Height / Q000187:drug effects* / Q000502:physiology; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D004393:Dwarfism, Pituitary / Q000188:drug therapy* / Q000503:physiopathology; D013006:Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D053580:Muscle Strength / Q000187:drug effects* / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D013006:Growth Hormone